At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 98 enrolled
Drug / intervention
Midodrine HCl +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Randomized-withdrawal, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects With Symptomatic Orthostatic Hypotension
In Brief
A Phase 4 clinical trial evaluating Midodrine HCl and Placebo for Symptomatic Orthostatic Hypotension. Completed, enrolled 98 participants across 32 sites in 4 countries.
Detailed Summary
To study the effect of midodrine against the symptoms of orthostatic hypotension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSymptomatic Orthostatic Hypotension
CountriesCzechia, Poland, Slovakia, United States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartMay 2012
Primary CompletionNov 2013
TodayJul 2026
First PostedJan 24, 2012
Enrollment StartMay 23, 2012
Primary CompletionNov 11, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.4 years ago
Interventions
Midodrine HCldrug
dose at subject's current dose level
Placebodrug
single dose of matching placebo